BHC Bausch Health Companies Inc.

22.17
+0.83  (+4%)
Previous Close 21.34
Open 21.57
Price To Book 3
Market Cap 7,809,771,473
Shares 349,757,253
Volume 7,333,411
Short Ratio 3.12
Av. Daily Volume 3,328,790
Stock charts supplied by TradingView

NewsSee all news

  1. Bausch Health's Ortho Dermatologics Business To Present Data At The Fall Clinical Dermatology Conference

    18 Poster Presentations on Investigational and Existing Products LAVAL, Quebec, Oct. 15, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its dermatology business, Ortho Dermatologics, one of the largest

  2. Ortho Dermatologics Announces 2019 Aspire Higher Scholarship Recipients

    $10,000 Scholarships Awarded to Nine Students Affected by Dermatologic Conditions LAVAL, Quebec, Oct. 10, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its dermatology business, Ortho Dermatologics,

  3. Bausch + Lomb Announces New Scientific And Clinical Analyses To Be Presented During The American Academy Of Ophthalmology And American Academy Of Optometry Annual Meetings

    BRIDGEWATER, N.J., Oct. 7, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced that 14 new scientific

  4. Bausch Health Companies Inc. Will Release Third-Quarter 2019 Financial Results on November 4

    LAVAL, Quebec, Oct. 4, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health") will release its third-quarter 2019 financial results on Monday, Nov. 4, 2019. Bausch Health will host a

  5. Bausch Health Files Lawsuit Against Sandoz For Infringement Of Patents Protecting XIFAXAN® 550 mg Tablets

    BRIDGEWATER, N.J., Oct. 1, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") along with its wholly owned subsidiary, Salix Pharmaceuticals ("Salix"),

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval announced May 7, 2018.
Plenvu (NER1006)
Bowel cleansing
Approval announced November 2, 2017.
Latanoprostene bunod
Open angle glaucoma (OAG) or ocular hypertension (OHT)
FDA approval announced February 25, 2019.
Loteprednol Gel 0.38%
Ocular Inflammation
Approval announced December 22, 2017.
LUMIFY (brimonidine tartrate ophthalmic solution 0.025%)
Eye Brightener
FDA Approval announced August 24, 2018.
IDP-121
Acne
Tentative FDA Approval announced October 8, 2018. Final approval expected November 2018 pending the expiration of exclusivity for a related product.
IDP-122
Psoriasis
NDA filing due 2020.
IDP-120
Acne
FDA approval announced April 25, 2019.
DUOBRII (halobetasol propionate and tazarotene)
Psoriasis
PDUFA date December 22, 2019.
IDP-123
Psoriasis
Approved February 15, 2017.
Brodalumab
Psoriasis
Approval announced March 2, 2018.
ULTRA - 7 days
Contact lens
CRL issued June 12, 2019
EM-100
Allergic conjunctivitis

Latest News

  1. Bausch Health's Ortho Dermatologics Business To Present Data At The Fall Clinical Dermatology Conference

    18 Poster Presentations on Investigational and Existing Products LAVAL, Quebec, Oct. 15, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its dermatology business, Ortho Dermatologics, one of the largest

  2. Ortho Dermatologics Announces 2019 Aspire Higher Scholarship Recipients

    $10,000 Scholarships Awarded to Nine Students Affected by Dermatologic Conditions LAVAL, Quebec, Oct. 10, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its dermatology business, Ortho Dermatologics,

  3. Bausch + Lomb Announces New Scientific And Clinical Analyses To Be Presented During The American Academy Of Ophthalmology And American Academy Of Optometry Annual Meetings

    BRIDGEWATER, N.J., Oct. 7, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced that 14 new scientific

  4. Bausch Health Companies Inc. Will Release Third-Quarter 2019 Financial Results on November 4

    LAVAL, Quebec, Oct. 4, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health") will release its third-quarter 2019 financial results on Monday, Nov. 4, 2019. Bausch Health will host a

  5. Bausch Health Files Lawsuit Against Sandoz For Infringement Of Patents Protecting XIFAXAN® 550 mg Tablets

    BRIDGEWATER, N.J., Oct. 1, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") along with its wholly owned subsidiary, Salix Pharmaceuticals ("Salix"),

  6. Bausch Health Releases 2018 Corporate Social Responsibility Report

    Second Annual Report Reinforces the Company's Continued Commitment to Responsible, Ethical and Sustainable Operations LAVAL, Quebec, Sept. 10, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC)

  7. Bausch Health To Reduce Debt By Approximately $200 Million Using Cash Flow From Operations

    LAVAL, Quebec, Sept. 3, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by approximately $200 million through the

  8. Bausch Health Companies Announces Participation In Upcoming Investor Conferences

    LAVAL, Quebec, Aug. 29, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) today announced that the Company will participate in three investor conferences. Paul S. Herendeen, executive vice president and chief